

Madagascar

| High HIV burden |

Tuberculosis profile

Population 2013

23 million

Estimates of TB burden * 2013	Number (thousands)	Rate (per 100 000 population)
Mortality (excludes HIV+TB)	12 (7.7–16)	52 (34–69)
Mortality (HIV+TB only)	0.43 (0.32–0.54)	1.9 (1.4–2.4)
Prevalence (includes HIV+TB)	95 (50–150)	413 (216–671)
Incidence (includes HIV+TB)	53 (47–60)	233 (207–262)
Incidence (HIV+TB only)	0.99 (0.88–1.1)	4.3 (3.8–4.9)
Case detection, all forms (%)	50 (44–56)	

Estimates of MDR-TB burden * 2013	New	Retreatment
% of TB cases with MDR-TB	0.5 (0.1–1.3)	3.9 (0.5–14)
MDR-TB cases among notified pulmonary TB cases	99 (20–260)	94 (12–330)

TB case notifications 2013	New **	Relapse
Pulmonary, bacteriologically confirmed	17 808	1 531
Pulmonary, clinically diagnosed	1 991	
Extrapulmonary	5 231	

Total new and relapse	26 561
Previously treated, excluding relapses	884
Total cases notified	27 445

Reported cases of RR-/MDR-TB 2013	New	Retreatment	Total **
Cases tested for RR-/MDR-TB	144 (<1%)	262 (11%)	421
Laboratory-confirmed RR-/MDR-TB cases			26
Patients started on MDR-TB treatment			12

TB/HIV 2013	Number	(%)
TB patients with known HIV status	5 412	(20)
HIV-positive TB patients	82	(2)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)		
HIV-positive TB patients on antiretroviral therapy (ART)	82	(100)
HIV-positive people screened for TB		
HIV-positive people provided with IPT		

Treatment success rate (%)	(%)
New and relapse cases registered in 2012	82
Previously treated cases, excluding relapse, registered in 2012	77
HIV-positive TB cases, all types, registered in 2012	
RR-/MDR-TB cases started on second-line treatment in 2011	
XDR-TB cases started on second-line treatment in 2011	


Laboratories 2013	
Smear (per 100 000 population)	1.0
Culture (per 5 million population)	0.2
Drug susceptibility testing (per 5 million population)	0.2
Sites performing Xpert MTB/RIF	5
Is second-line drug susceptibility testing available?	No

Financing TB control 2014	
National TB programme budget (US\$ millions)	2.9
% Funded domestically	7%
% Funded internationally	93%
% Unfunded	0%

* Ranges represent uncertainty intervals


** Includes cases with unknown previous TB treatment history

(Rate per 100 000 population per year)




Mortality (excludes HIV+TB)

(Rate per 100 000 population)




Prevalence

(Rate per 100 000 population per year)




Notified (new and relapse) Incidence
Incidence (HIV+TB only)

(Number of patients)




HIV-positive TB patients
on CPT on ART

Treatment success rate (%)



New Retreatment
New and relapse Retreatment, excluding relapse
HIV-positive RR-/MDR-TB XDR-TB

Total budget (US\$ millions)



Funded domestically Funded internationally
Unfunded